<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02577029</url>
  </required_header>
  <id_info>
    <org_study_id>Heparc-2008</org_study_id>
    <nct_id>NCT02577029</nct_id>
  </id_info>
  <brief_title>Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic HBV</brief_title>
  <acronym>Monarch</acronym>
  <official_title>A Multicenter, Open-Label Study to Evaluate ARC-520 Administered Alone and in Combination With Other Therapeutics in Patients With Chronic Hepatitis B Virus (HBV) Infection (MONARCH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arrowhead Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arrowhead Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with chronic Hepatitis B Virus (HBV) infection will receive either ARC-520 alone or
      ARC-520 in combination with other treatments such as entecavir (ENT) or tenofovir (TDF)
      and/or pegylated interferon alpha 2a (PEG IFN) therapy, and be evaluated for safety and
      efficacy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open-label study of ARC-520 based treatment regimens administered to
      patients with HBeAg positive or HBeAg negative immune active chronic Hepatitis B Virus (HBV)
      infection of various genotypes, or patients with Hepatitis D Virus (HDV). Eligible patients
      naive to previous treatment, and who have signed an Ethics Committee - approved informed
      consent, will be enrolled and will receive ARC-520 alone or ARC-520 plus additional
      treatments such as entecavir (ENT) or tenofovir (TDF) and/or pegylated interferon alpha 2a
      (PEG IFN) therapy. The study may initially involve up to a total of 96 eligible chronic HBV
      and HDV infected patients. Patients in all cohorts will receive a total of 13 doses of
      ARC-520 at 2mg/kg or 4 mg/kg. Patients will undergo the following evaluations at regular
      intervals during the study: medical history, physical examinations, vital sign measurements
      (blood pressure, heart rate, respiratory rate, and temperature), weight, adverse events
      assessment (AEs), 12-lead ECGs, liver fibrosis testing, concomitant medication assessment,
      blood sample collection for hematology, coagulation, chemistry, exploratory Pharmacodynamic
      (PD) measures, urinalysis, HBV serology, cytokines, Follicle Stimulating Hormone (FSH)
      testing (post-menopausal females) and pregnancy testing for females of childbearing
      potential. Clinically significant changes including AEs will be followed until resolution,
      until the condition stabilizes, until the event is otherwise explained, or until the patient
      is lost to follow-up. For each patient, the duration of the study is approximately 96 weeks,
      from enrolment to last visit. Prior to enrolment there is a 60 day screening period. Addition
      of new cohorts and additional treatment regimens are anticipated for this study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Company decision to discontinue trial
  </why_stopped>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients achieving a 1-log reduction in Hepatitis B Surface Antigen (HBsAg) compared to baseline</measure>
    <time_frame>Baseline to Week 60</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with HBsAg loss (based on qualitative assay) compared to baseline</measure>
    <time_frame>Baseline and Weeks 52, 60, 72 and 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving a 1-log reduction in HBsAg and achieving a HBsAg level &lt; 100 IU/L compared to baseline</measure>
    <time_frame>Baseline and Weeks 52, 60, 72 and 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to HBsAg loss</measure>
    <time_frame>Baseline through Week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to anti-HBs (antibody to Hepatitis B Surface Antigen) seroconversion</measure>
    <time_frame>Baseline through Week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with anti-HBs seroconversion compared to baseline</measure>
    <time_frame>Baseline and Weeks 52, 60, 72 and 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with Hepatitis B e Antigen (HBeAg) loss and Anti Hepatitis B e Antigen (Anti-HBe) seroconversion compared to baseline (if HBeAg positive at study entry)</measure>
    <time_frame>Baseline and Weeks 52, 60, 72 and 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with resistance to ARC-520 compared from baseline to Week 52</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>Resistance defined as &gt; 1.0 log IU/mL quantitative HBsAg (qHBsAg) increase from nadir, confirmed by repeat test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with resistance to the combination therapy from baseline to Week 60</measure>
    <time_frame>Baseline and Week 60</time_frame>
    <description>Resistance defined as &gt; 1.0 log IU/mL increase in HBV DNA from nadir, confirmed by repeat test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and frequency of adverse events as a measure of safety and tolerability of ARC-520 alone or when coadministered with combination therapy</measure>
    <time_frame>Baseline to Week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of HDV patients with undetectable HDV ribonucleic acid (RNA) after 48 weeks of concomitant ARC-520 and PEG IFN therapy</measure>
    <time_frame>At Weeks 52, 60, 72 and 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Log change from baseline in quantitative HBV deoxyribonucleic acid (DNA)</measure>
    <time_frame>Baseline and Weeks 52, 60, 72 and 96</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Hepatitis B</condition>
  <condition>Hepatitis D</condition>
  <arm_group>
    <arm_group_label>ARC-520 administered alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ARC-520 (2 mg/kg or 4 mg/kg every 4 weeks) for 48 weeks (13 doses).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARC-520 with nucleoside and Peginterferon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ARC-520 (2 mg/kg every 4 weeks - 48 weeks) + entecavir (0.5 mg daily - about 60 weeks) or tenofovir (300 mg daily - about 60 weeks) + Peginterferon alpha 2a (180 mcg weekly) - 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARC-520 with Peginterferon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ARC-520 (2 mg/kg every 4 weeks - 48 weeks) + Peginterferon alpha 2a (180 mcg weekly) - 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARC-520</intervention_name>
    <arm_group_label>ARC-520 administered alone</arm_group_label>
    <arm_group_label>ARC-520 with nucleoside and Peginterferon</arm_group_label>
    <arm_group_label>ARC-520 with Peginterferon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <arm_group_label>ARC-520 with nucleoside and Peginterferon</arm_group_label>
    <other_name>Baraclude</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pegylated Interferon alpha 2a</intervention_name>
    <arm_group_label>ARC-520 with nucleoside and Peginterferon</arm_group_label>
    <arm_group_label>ARC-520 with Peginterferon</arm_group_label>
    <other_name>Peginterferon</other_name>
    <other_name>Pegasys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir disoproxil</intervention_name>
    <arm_group_label>ARC-520 with nucleoside and Peginterferon</arm_group_label>
    <other_name>Viread</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, 18 to 75 years of age

          -  Written informed consent

          -  No clinically significant abnormalities at screening/pre-dose 12-lead ECG assessment

          -  Diagnosis of HBeAg negative or positive chronic HBV infection.

          -  Must be HBsAg (+) during screening.

          -  Must be treatment na√Øve: Never on pegylated interferon alpha 2a (PEG INF) and/or
             entecavir (ETV) or tenofovir (TDF); and

          -  Have not used nucleoside/nucleotide analogs (NUCs) within the last 2 years prior to
             dosing on Day 1

          -  Must use 2 effective methods of contraception (double barrier contraception or
             hormonal contraceptive along with a barrier contraceptive) (both male and female
             partners)

        Exclusion Criteria:

          -  Pregnant or lactating

          -  Acute signs of hepatitis/other severe infections within 4 weeks of screening

          -  Use within the last 14 days or anticipated requirement for anticoagulants, systemic
             corticosteroids, immunomodulators, or immunosuppressants

          -  Use of prescription medication within 14 days prior to treatment administration
             except: topical products without systemic absorption, statins (except rosuvastatin),
             hypertension medications, over-the-counter (OTC) and prescription pain medication or
             hormonal contraceptives

          -  History of poorly controlled autoimmune disease or any history of autoimmune hepatitis

          -  History of heterozygous or homozygous familial hypercholesterolemia.

          -  Human immunodeficiency virus (HIV) infection

          -  Is sero-positive for Hepatitis C Virus (HCV), or has a history of delta virus
             hepatitis (except for cohort in which delta virus infection is acceptable)

          -  Has hypertension: blood pressure &gt; 170/100 mmHg; well-controlled blood pressure on
             hypertensive medication allowed.

          -  History of cardiac rhythm disturbances

          -  Family history of congenital long QT syndrome, Brugada syndrome or unexplained sudden
             cardiac death

          -  Symptomatic heart failure, unstable angina, myocardial infarction, severe
             cardiovascular disease within 6 months prior to study entry

          -  History of malignancy, except for adequately treated basal cell carcinoma, squamous
             cell skin cancer, superficial bladder tumors, or in situ cervical cancer

          -  Has had major surgery within 1 month of screening

          -  Regular use of alcohol within 6 months prior to screening (ie, more than 14 units of
             alcohol per week).

          -  Use of recreational drugs such as cocaine, phencyclidine (PCP), and methamphetamines,
             within 1 year prior to the screening.

          -  History of allergy to bee sting

          -  Clinically significant history of any alcoholic liver disease, cirrhosis, Wilson's
             disease, hemochromatosis, or alpha-1 antitrypsin deficiency

          -  Presence of cholangitis, cholecystitis, cholestasis, or duct obstruction

          -  Clinically significant history or presence of poorly controlled/uncontrolled systemic
             disease

          -  Presence of any medical or psychiatric condition or social situation that impacts
             compliance or results in additional safety risk

          -  History of coagulopathy/stroke within past 6 months, and/or concurrent anticoagulant
             medication(s)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Concord Repatriation General Hospital, Gastroenterology &amp; Liver Services</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital Sydney</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Health Clayton Campus</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital Melbourne</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research Ltd.</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT St. Pantaleimon OOD, Department of Gastroenterology</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT St. Ivan Rilski EAD, Clinic of Gastroenterology</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic and Consultative Center - Focus 5 - Outpatient Medical Center, EOOD</name>
      <address>
        <city>Sofia</city>
        <zip>1463</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic and Consultative Center Mladost-M Varna</name>
      <address>
        <city>Varna</city>
        <zip>9020</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital, Department of Medicine</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>41944</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>3080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>6273</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMSP Spitalul Clinic de Boli Infectioase, Toma Ciorba</name>
      <address>
        <city>Chisinau</city>
        <zip>MD-2004</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Middlemore Clinical Trials, Middlemore Hospital</name>
      <address>
        <city>Papatoetoe</city>
        <state>Aukland</state>
        <zip>2025</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dunedin Hospital, Gastroenterology Research Unit</name>
      <address>
        <city>Dunedin</city>
        <state>Otago-Southland</state>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland Clinical Studies</name>
      <address>
        <city>Auckland</city>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital, Yun-Lin Branch</name>
      <address>
        <city>Douliou</city>
        <state>Yunlin County</state>
        <zip>640</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changhua Christian Hospital</name>
      <address>
        <city>Changhua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Chulalongkorn Memorial Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Tropical Diseases</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phramongkutklao Hospital, Division of Digestive and Liver Disease</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maharaj Nakhon Chiang Mai Hospital, Gastroenterology Division</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Khon Kaen University</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thammasat University Hospital, Gastroenterology Unit</name>
      <address>
        <city>Pathumthani</city>
        <zip>12120</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Bulgaria</country>
    <country>China</country>
    <country>Korea, Republic of</country>
    <country>Moldova, Republic of</country>
    <country>New Zealand</country>
    <country>Taiwan</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2015</study_first_submitted>
  <study_first_submitted_qc>October 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2015</study_first_posted>
  <last_update_submitted>January 17, 2017</last_update_submitted>
  <last_update_submitted_qc>January 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis D</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>December 18, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

